ArticleCancers2022

Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers.

Jesus Garcia-Foncillas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.